PAVmed Inc.

Name: PAVmed Inc. standardized financial statements, quarterly
Creator: Listed

PAVMNasdaqCIK 1624326HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$33.0k, Q2 FY2026

Operating income−$7.0m, Q2 FY2026

Net income−$5.4m, Q2 FY2026

PAVmed Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.8	1.0	1.0	1.0	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
Cost of revenue	$m	1.8	1.6	1.7	1.7	1.4	0.0	0.0	0.0	0.1	0.1	0.1	0.1
Gross profit	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	3.2	3.6	1.9	1.6	1.5	0.8	0.8	0.8	1.1	1.8	1.4	2.1
Operating income	$m	(15.5)	(16.4)	(14.0)	(13.7)	(11.6)	(5.2)	(5.4)	(4.7)	(4.8)	(6.8)	(8.0)	(7.0)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	0.0	0.0	0.0	(0.0)	0.0	0.0
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	0.0	0.0	not reported	not reported	0.0	0.0
Net income	$m	(17.7)	(14.0)	(15.2)	(10.8)	64.4	1.4	19.0	(11.9)	(5.4)	(1.3)	(0.1)	(5.4)
Diluted EPS	$ per share	(2.38)	not reported	(2.62)	(1.19)	1.44	not reported	10.10	(22.08)	(0.29)	not reported	(4.42)	(0.87)
Basic EPS	$ per share	(2.38)	not reported	(2.62)	(1.19)	6.43	not reported	38.26	(22.08)	(0.29)	not reported	(4.42)	(0.87)

Balance sheet

Cash and equivalents$3.8m, Q2 FY2026

Shareholders' equity$35.0m, Q2 FY2026

PAVmed Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	period not labelled2025-02-14	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	19.6	25.5	25.5	0.8	1.2	not reported	2.7	4.0	3.1	1.5	6.5	3.8
Current assets	$m	24.5	29.6	30.2	2.1	2.2	not reported	3.6	5.5	4.2	2.6	7.4	4.9
Total assets	$m	33.1	37.3	39.4	30.6	30.7	not reported	52.8	43.9	38.1	38.8	45.4	40.2
Current liabilities	$m	54.2	55.0	53.4	37.6	35.4	not reported	9.8	10.5	10.5	14.8	3.7	4.1
Total liabilities	$m	57.1	57.8	58.1	39.9	37.7	not reported	11.9	12.5	12.3	16.5	20.4	20.9
Shareholders' equity	$m	(53.8)	(68.8)	(73.9)	(4.9)	(2.5)	2.5	45.0	37.5	32.5	34.0	39.5	35.0

Cash flow

Operating cash flow−$2.7m, Q2 FY2026

Capital expenditure$13.0k, Q2 FY2026

PAVmed Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(11.1)	(11.9)	(13.1)	(11.7)	(8.9)	0.1	(1.6)	(1.2)	(0.9)	(1.6)	(2.6)	(2.7)
Capital expenditure	$m	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)6.27m, Q2 FY2026

PAVmed Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	89.8	6.5	7.0	7.5	8.7	9.2	44.5	1.7	0.6	21.6	1.6	6.3

Shares outstanding: 8.00m at Aug 13, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.